Welcome

Bluebird Is Sued Over Patents Related to Blood-Disease Drug

Oct. 21, 2021, 9:56 PM

Bluebird Bio’s LentiGlobin and Zynteglo infringe two patents for recombinant vectors used in the treatment of rare blood disorders, closely held Errant Gene Therapeutics claims in a new lawsuit.

  • Recombinant vectors deliver gene fragments used in vaccines to boost the immune system
  • Bluebird in September submitted to FDA its application for beti-cel, made using BB305 lentiviral vector, and it’s marketing beti-cel as LentiGlobin for treating sickle cell disease and as Zynteglo for beta thalassemia, according to a complaint filed Thursday in federal court in Wilmington, Delaware
  • Errant is seeking at least a reasonable royalty and either court order blocking ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.